GSA Capital Partners’s Immuneering IMRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$415K Sell
101,336
-241,967
-70% -$1.14M 0.02% 1192
2026
Q2
$1.71M Buy
343,303
+266,551
+347% +$1.35M 0.11% 221
2026
Q1
$404K Buy
+76,752
New +$393K 0.03% 1052
2025
Q4
– Sell
-37,836
Closed -$265K – 1860
2025
Q3
$265K Buy
+37,836
New +$196K 0.02% 1271
2023
Q1
– Sell
-23,371
Closed -$113K – 1683
2022
Q4
$113K Sell
23,371
-9,739
-29% -$86.3K 0.01% 1290
2022
Q3
$474K Buy
+33,110
New +$263K 0.06% 608

Other funds holding IMRX

GSA Capital Partners's IMRX Position: Q3 2026 in Review

GSA Capital Partners reduced its Immuneering (IMRX) stake by 70% in Q3 2026, selling an estimated $1.14M and leaving 101,336 shares worth $415K. The position accounts for 0.02% of the portfolio, ranked #1192.

GSA Capital Partners first reported a position in IMRX in Q3 2022 and has held it in 6 quarters since. The position peaked at $1.71M in Q2 2026. 131 funds tracked by Wall St. Rank hold IMRX as of Q3 2026.

  • GSA Capital Partners held 101,336 shares of Immuneering worth $415K as of Q3 2026.
  • GSA Capital Partners sold 241,967 Immuneering shares in Q3 2026, an estimated $1.14M.
  • Immuneering made up 0.02% of GSA Capital Partners's portfolio in Q3 2026, its #1192 holding.
  • GSA Capital Partners first reported a position in Immuneering in Q3 2022 and has held it in 6 quarters since.
  • GSA Capital Partners's Immuneering position peaked at $1.71M in Q2 2026.
  • 131 funds tracked by Wall St. Rank held Immuneering as of Q3 2026.

Based on GSA Capital Partners's 13F filing for Q3 2026, filed 16 Nov 2026.